Our results suggest a novel mechanism through which pharmacological blockade of FASN-catalyzed endogenous lipogenesis might promote an ERα-related suppression of E2-stimulated breast cancer cell growth and survival. The gene discussed is ESR1; the disease is breast carcinoma.